Tirzepatide and Menopause Hormone Therapy Found to Boost Weight Loss in Postmenopausal Women with Overweight or Obesity

Strategic Insights -

Women with menopause who receive hormone therapy in addition to tirzepatide for weight loss experienced significantly greater weight loss than those who did not, according to a study presented at ENDO 2025. The research team, led by Dr. Dima Bechenati from the Mayo Clinic, analyzed data from 120 postmenopausal women with overweight or obesity who received tirzepatide and were either taking menopausal hormone therapy (MHT) or not. The results showed that the group taking MHT achieved 17% total body weight loss, compared to 14% in the group not taking MHT. Additionally, 45% of women in the MHT group achieved 20% or more total body weight loss, compared to 18% in the group not taking MHT.

Key Takeaways:

  • The study found that postmenopausal women with overweight or obesity who received tirzepatide and menopausal hormone therapy (MHT) achieved significantly greater total body weight loss than those who did not receive MHT.
  • The median follow-up duration was 18 months for both the MHT and non-MHT groups.
  • The proportion of women who achieved 20% or more total body weight loss by the last follow-up was higher in the MHT group (45%) compared to the non-MHT group (18%).
  • Dr. Regina Castaneda, coauthor of the study, stated that the data show a combined use of tirzepatide and menopause hormone therapy increases treatment effectiveness in postmenopausal women.
  • The study was presented at ENDO 2025, the annual meeting of the Endocrine Society.
  • Dr. Dima Bechenati and his team at the Mayo Clinic conducted the analysis.

Statistics:

  • Total body weight loss achieved by the +MHT group at the last follow-up: 17%
  • Total body weight loss achieved by the â'MHT group at the last follow-up: 14%
  • Proportion of women in the +MHT group who achieved 20% or more total body weight loss by the last follow-up: 45%
  • Proportion of women in the â'MHT group who achieved 20% or more total body weight loss by the last follow-up: 18%
  • Follow-up duration for both groups: 18 months (median)

Sources:

  • HealthDay News, July 15, 2025
  • ENDO 2025, The annual meeting of the Endocrine Society, San Francisco, CA, July 12-15, 2025
  • Mayo Clinic, Rochester, MN, USA
  • Dima Bechenati, M.D. (Mayo Clinic)
  • Regina Castaneda, M.D. (Mayo Clinic)